A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Summary

The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14C\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.

Eligibility

Inclusion Criteria

* Participants must have an advanced, unresectable, or metastatic solid tumor malignancy with a deletion of the methylthioadenosine phosphorylase (MTAP) gene.
* Participants must have received, be refractory to, be ineligible for, or be intolerant of available standard care for their cancer.

Exclusion Criteria

* Participants must not have a history of any surgical or medical conditions possibly affecting how the study drug is distributed, broken down (metabolized) and removed (excreted or eliminated) from the body.
* Participants must not have participated in a clinical study involving a radiolabeled study drug within 12 months prior to admission to the research center.
* Participants must not have a current or recent (within 3 months of study drug administration) gastrointestinal disease.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Conditions2

Interventions2

Related trials

• A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors — Bristol-Myers Squibb
• A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) — Bristol-Myers Squibb
• A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion — Bristol-Myers Squibb
• A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) — Bristol-Myers Squibb
• Clinical Trial of BMS-986504 in Recurrent GBM Patients — Nader Sanai
• A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer — Memorial Sloan Kettering Cancer Center
• A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer — M.D. Anderson Cancer Center

Browse More Trials